Novo Nordisk defends disappointing next-gen obesity drug: 'It will be an important product'
Novo Nordisk has defended disappointing trial results for its much-hyped next generation obesity drug candidate CagriSema, insisting it will be an "important" weight loss treatment. "I'm very confident about CagriSema," he told shareholders at the firm's Annual General Meeting in Copenhagen, Denmark.
BoFA says Novo Nordisk may miss Q1 expectations as Wegovy, Ozempic sales lag
Bank of America analysts on Friday said Novo Nordisk may miss first-quarter expectations, as sales of its blockbuster Wegovy and Ozempic drugs lag, which could prompt the Danish drugmaker to cut its 2025 guidance in its quarterly results.
Novo Nordisk should steady nerves by restating growth targets alongside Q1 results
JP Morgan expects Novo Nordisk (NYSE:NVO) to hold the line on its 2025 growth targets when it reports first-quarter results, saying a reaffirmation of guidance would help calm nerves after a sluggish start to the year for weight-loss drug Wegovy in the US. Analyst Richard Vosser forecasts sales of DKr77.1bn, around 4% below Bloomberg consensus estimates, largely due to lower expectations for both Wegovy and diabetes treatment Ozempic.
Lexicon to license obesity drug to Novo Nordisk in up to $1 billion deal
Lexicon Pharmaceuticals said on Friday it has entered into an agreement with Novo Nordisk to license its non-incretin-based experimental obesity drug for up to $1 billion.
Why Novo Nordisk Stock Dipped on Thursday
Novo Nordisk's (NVO -2.13%) is famous and celebrated for its cutting-edge obesity medication. But on Thursday, its stock felt like the company ingested some of its own treatment.
Novo Nordisk says copycat compounders are hurting Wegovy sales, may take legal action
Obesity drug giant Novo Nordisk said Thursday that the rampant growth of the U.S.'s compounded drug industry was hurting Wegovy sales. CEO Lars Fruergaard Jørgensen told shareholders at its Annual General Meeting that it was pursuing legal action against companies it believes to be violating its intellectual property.
Novo shares on track for biggest monthly fall since 2002, investor worries grow
Novo Nordisk shares have fallen 25% so far in March and are on track for their biggest monthly drop since July 2002, as investor worries intensify that the obesity drug market pioneer has lost its edge over U.S. Eli Lilly.
1 Growth Stock Down 40% to Buy and Hold Forever
This might surprise some, but Danish pharmaceutical giant Novo Nordisk (NVO -2.29%) has significantly lagged the market in the past year. The drugmaker's shares are down by 40% over the trailing-12-month period, despite grabbing headlines for its work in the red-hot weight management drug market.
Novo Nordisk Stock Sinks To 52-Week Lows: Weight Loss Boom Losing Steam?
Novo Nordisk A/S NVO has been on a tear in the weight loss drug race, but its stock is slimming down for all the wrong reasons.
Is Novo Nordisk Stock a Buy?
There is a long-running health crisis impacting the modern world. According to the World Health Organization, one in eight people worldwide were living with obesity as of 2022.
Novo Nordisk Expands Wegovy Price Cut Program, Stock Still Falls 2%
NVO's shares are down 2% despite making Wegovy available at a discounted price of $499 per month at local pharmacies.
Why Novo Nordisk Stock Dropped on Monday, but Eli Lilly and Him & Hers Health Popped
Novo Nordisk (NVO -2.06%) stock slipped 1.7% through 12:10 a.m. ET Monday on a pair of news items with which investors seem less than thrilled:
